Bicara Therapeutics Common Stock Current Cash

Bicara Therapeutics Common Stock (BCAX) currently reports a current cash of $97M as of June 2026. That compares with $440M in the prior-year period — down 77.9% year over year. Use the charts on this page to explore Bicara Therapeutics Common Stock's current cash history and peer comparisons.

Bicara Therapeutics Common Stock's current cash decreased from $440M to $97M — a 77.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bicara Therapeutics Common Stock reported $97M in current cash as of June 2026. That compares with $440M in the prior-year period — down 77.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $97M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bicara Therapeutics Common Stock, and consider following BCAX for alerts when major investors trade the stock.

Bicara Therapeutics Common Stock is classified in the Healthcare sector. On current cash, it currently shows $97M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCAX with unrelated industries.